Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

llaboration with Novartis covering Genelabs' non-nucleoside HCV polymerase inhibitors.

"The data presented today clearly support the further investigation of non-nucleoside polymerase inhibitors for the future treatment of HCV infection," said Ronald C. Griffith, Ph.D., Genelabs' Chief Scientific Officer. "Furthermore, we believe future treatment of HCV is likely to involve combinations of antiviral drugs and these data suggest that combinations of this type of non-nucleoside agent with interferon or other likely therapeutic drugs, such as nucleoside chain terminators or protease inhibitors, may be feasible."

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

NOTE: Genelabs(R) and the Genelabs logo are registered trademarks and Prestara(TM) is a trademark of Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements on the feasibility of non-nucleoside polymerase inhibitors for the future treatment of HCV infection and the prospects fo
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... a stock purchase agreement to acquire 100% of QCR ... based distribution organization. The transaction closed on ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... In the year since a devastating earthquake struck Haiti on ... world have launched and supported projects to help the country ... began, Rotary clubs started a $200,000 initiative to implement cholera ... waterborne disease. Rotary clubs worldwide have contributed more ...
... Cardinal Health plans to release second-quarter financial results for its ... of trading on the New York Stock Exchange. ... Feb. 3 at 8:30 a.m. EST to discuss second-quarter results. ... the Investor page at cardinalhealth.com/investors or dial 857-350-1669 passcode 24786608. ...
Cached Medicine Technology:Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 2Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 3Cardinal Health to Release Second-Quarter Results on Feb. 3 2
(Date:11/23/2014)... 2014 BambooFlooringChina.com , the world’s leader ... strand woven bamboo flooring collection. Now, the business is ... company’s CEO, the promotion is valid until Dec. 20, 2014. ... a smooth and dust-free surface, which makes it very easy ... industry, the company wants to make its website the best ...
(Date:11/22/2014)... Cancer researchers in New York and ... communication tunnels and the growth and spread of mesothelioma. ... on the Surviving Mesothelioma website. , Doctors at ... Minnesota have just released their study on tunneling nanotubes ... cells. They found that mesothelioma cells contain ...
(Date:11/22/2014)... Recently, Locks-Magnetic.com , one of ... promotion of mag locks for glass doors online. In ... on these fresh products. Customers can get more information ... doors are in excellent performance. Customers who want to ... soon as possible. They also can enjoy the ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 "My ... the pain caused by the machine," said an inventor ... she had to go back a second time because ... invention idea." , She developed the patent-pending MAMO EASY ... breast cancer. The design saves the patient from the ...
Breaking Medicine News(10 mins):Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2
... ... Club, the Endangered Habitats League and SOS Hills will honor "Avatar" ... Outstanding Social Responsibility in Media. "Avatar,s" themes closely mirror the ... residents are facing against Granite Construction, a powerful corporation that wants ...
... ... medical experience. , ... Scottsdale, AZ (PRWEB) March 3, 2010 -- NightHawk Radiology Services, the leading ... named two new physician leaders to its Medical Executive Team (MET), an influential group ...
... , ... ... ... ...
... ... ... ... ...
... forms of Leukaemia have identified a new drug target to ... diseased cells. The research, reported in EMBO Molecular Medicine ... if targeted could prevent diseased cells from developing. The ... Vienna, carried out their research on acute lymphoid leukaemia (ALL) ...
... from injuries to the distal biceps tendon may benefit from ... review article published in the March 2010 issue of the ... (JAAOS). Located in the front of the elbow, the distal ... muscle, and is responsible for two primary motions: , ...
Cached Medicine News:Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 2Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 3Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 4Health News:NightHawk Radiology Services Expands Its Medical Executive Team 2Health News:NightHawk Radiology Services Expands Its Medical Executive Team 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 2Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 4Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 2Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 3Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 4Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 5Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 6Health News:Targeting leukemia cell's gene 'addiction' presents new strategy for treatment 2Health News:Battling a biceps injury 2Health News:Battling a biceps injury 3
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
Medicine Products: